Our Mission
By using open source principles, and by nurturing a movement, we seek to create low-cost new medicines in areas of great health need
Fair, Fast, and Open:
New Scientific and Legal Paradigms in Disease Prevention - Presentation to WHO Chief Scientist Dr. Soumya SwaminathanA special OSPF event! Welcome scientific luminaries Prof. Robert Gallo, Prof. Mihai Netea, Prof. Christine Stabell-Benn, and Dr. Subash Babu presenting their groundbreaking research on universal patent-free innate immunity vaccines to the renowned WHO Chief Scientist Dr. Soumya Swaminathan and the open source enthusiast community.
|
The New York Times
Why a Century-Old Vaccine Offers New Hope Against PathogensThe century-old BCG tuberculosis vaccine, accessible to billions, trusted by billions, and which costs only 15 cents a dose, shows 92% efficacy against COVID-19 in very small clinical trial by Professor Denise Faustman of Harvard Medical School. It is thought that the vaccine boosts the overall immune system. This exemplifies OSPF's 2+ year exploration of certain off patent vaccines, including BCG, against COVID-19, future pandemics and other diseases - a new scientific and legal/economic paradigm for vaccines. We cannot guarantee that they will work, but we absolutely must explore them. The New York Times article mentions OSPF. "“Imagine if we could use existing vaccines to curb pandemics — that would change world history,” Mr. Menon said."
|
Newsweek profiles OSPF as one of its "50 Greatest Disruptors: Visionaries and Innovators Who Are Changing the World"
Image from www.newsweek.com
The New Yorker features OSPF's universal open source vaccine work and approach
Beyond the Booster Shot: Could a “broad spectrum” booster increase our immunity to many pathogens simultaneously?
-Matthew Hutson, The New Yorker
Illustration by Nicholas Konrad / The New Yorker from www.newyorker.com
VACCINUUM
Universally Available, Ultra-Broad Spectrum Vaccines
Toward Universal Vaccines/ A Protective Layer for Humanity: Ultra-Broad Spectrum Open Source Vaccines to Protect Against SARS-CoV-2 Variants, Other Diseases, and Future Epidemics - Phase 3 Trials and Other Explorations
Neglected/Infectious Disease Knowledge GraphsOpen Source Pharma Foundation and Ingentium are collaborating on the implementation of an open information commons for the collaborative development of new disease treatments using an open source methodology, initially focusing on tuberculosis, Chikungunya, and Nipah virus.
|
FastCompany World Changing Ideas Awards 2020: AI and Data Finalists and Honorable MentionsOpen Source Pharma Foundation receives honorable mention for its work harnessing the power of data, machine learning, or artificial intelligence to understand the world and empower change
|
SUPPORT OUR WORK IN INDIA, USA, AND AROUND THE WORLD
PHASE 3 OPEN SOURCE COVID-19 VACCINE CLINICAL TRIAL
OSPF is a collaborator in a Phase 3 COVID-19 vaccine trial in Brazil, testing the efficacy of the off-patent MMR vaccine and of the low-cost influenza vaccine against the Gamma SARS-CoV-2 variant. The trial has commenced, with 6000 participants across three arms. Co-PI’s Prof. Mihai Netea, Radboud University, Netherlands, and Prof. Sergio Henrique Nascente Costa, Federal University of Goias. Brazil. Protocol summary here.
|
By HelloScience
|
|
Short Teaser
|
|
March 24, 2019
|
|
"I call on all countries, companies, and research institutions to support open data, open science, and open collaboration so all people can enjoy the benefits of science and research."
-Dr. Tedros Ghebreyesus, Director General of the World Health Organization (WHO) |
In partnership with the National Institute for Research in Tuberculosis in India, we have commenced phase 2b clinical trials |
OSPF is a proud supporter of the Open Source Pharma movement |
OSP3 - Paris - March 2019OSPF took part in the third conference for the open source pharma movement that was held between March 21st and 23rd, 2019 at the Center for Research and Interdisciplinarity (CRI) in Paris. For more information, visit the Open Source Pharma community website.
|
PRESS
Fast Company
How open-source medicine could prepare us for the next pandemic |
BBC News
'We should own our own livelihood and our own dream' |
The Lancet
Can open-source drug development deliver? |
Discovering the Person Who Will Discover the Molecule
|
|